# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Wells Fargo analyst Larry Biegelsen maintains NovoCure (NASDAQ:NVCR) with a Overweight and lowers the price target from $42 ...
HC Wainwright & Co. analyst Emily Bodnar maintains NovoCure (NASDAQ:NVCR) with a Neutral and raises the price target fro...
Evercore ISI Group analyst Vijay Kumar maintains NovoCure (NASDAQ:NVCR) with a In-Line and raises the price target from $14....